In solid tumors that express disialoganglioside GD2, such as glioblastoma, neuroblastoma, and lung cancer, T cells co-expressing GD2-specific CAR and IL-15 have demonstrated promising preclinical efficacy. This evidence concerns the gene IL15 and lung cancer.